Author

L. Metang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. Wang· 2 shared J. Gonzalez· 2 shared P. Mu· 2 shared S. Deng· 2 shared T. Wang· 2 shared X. Li· 2 shared Y. Wang· 2 shared Y. Xu· 2 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Wang

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers

P. Mu, Y. Xu, Z. Wang, M. Sjostrom, S. Deng, C. Wang, N. Jonhson, J. Gonzalez, X. Li, L. Metang, C. Rodriguez, A. Mukherji, G. Wainwright, X. Yu, Y. Yang, , T. Wang

This study shows ZNF397 loss leads to TET2-driven epigenetic changes, lineage plasticity, and resistance to AR-targeted therapies in AR-dependent cancers, with TET2 inhibitors reversing resistance.

Cancer Discovery · Apr 8, 2024Peer-reviewedCancer Biology

JAK-STAT Signaling Enables Lineage Plasticity-driven AR Targeted Therapy Resistance

S. Deng, C. Wang, Y. Wang, Y. Xu, X. Li, N. Johnson, U.-G. Lo, L. Xu, J. Gonzalez, L. Metang, J. Ye, C. R. Tirado, K. Rodarte, Z. Xie, C. Arana, , P. Mu

The paper identifies JAK-STAT signaling as a key driver of lineage plasticity-driven resistance to AR targeted therapy in prostate cancer using integrated transcriptomic and scRNA-Seq analysis.

bioRxiv · Nov 2, 2021Cancer Biology